 Cecilia Low Wang
Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperglycemia | 8 | 2024 | 327 | 2.530 |
Why?
| | Diabetes Mellitus, Type 2 | 17 | 2025 | 2444 | 2.390 |
Why?
| | Blood Glucose | 14 | 2025 | 2103 | 1.480 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2008 | 1.350 |
Why?
| | Diabetes Mellitus | 7 | 2021 | 1003 | 1.320 |
Why?
| | Lower Extremity | 4 | 2024 | 407 | 1.210 |
Why?
| | Hypoglycemic Agents | 8 | 2025 | 1221 | 1.150 |
Why?
| | Cardiovascular System | 2 | 2019 | 136 | 1.050 |
Why?
| | Peripheral Arterial Disease | 4 | 2024 | 458 | 1.000 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2024 | 443 | 0.950 |
Why?
| | Community Health Workers | 1 | 2025 | 59 | 0.910 |
Why?
| | Prediabetic State | 2 | 2024 | 244 | 0.870 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 430 | 0.690 |
Why?
| | Blood Glucose Self-Monitoring | 3 | 2025 | 601 | 0.680 |
Why?
| | Epidemics | 1 | 2021 | 82 | 0.650 |
Why?
| | Aspirin | 2 | 2024 | 380 | 0.640 |
Why?
| | Hypoglycemia | 1 | 2024 | 427 | 0.620 |
Why?
| | Insulin Resistance | 7 | 2024 | 1168 | 0.620 |
Why?
| | Drug Approval | 1 | 2019 | 87 | 0.600 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 15 | 0.590 |
Why?
| | Glucocorticoids | 3 | 2022 | 582 | 0.580 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 231 | 0.580 |
Why?
| | Sample Size | 1 | 2018 | 116 | 0.570 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1005 | 0.540 |
Why?
| | Insulin | 10 | 2024 | 2330 | 0.520 |
Why?
| | Atherosclerosis | 3 | 2017 | 402 | 0.510 |
Why?
| | Ischemia | 1 | 2018 | 405 | 0.480 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 39 | 0.480 |
Why?
| | Drugs, Investigational | 1 | 2015 | 32 | 0.480 |
Why?
| | Hospitals | 2 | 2017 | 649 | 0.470 |
Why?
| | Patient Care Planning | 1 | 2016 | 146 | 0.460 |
Why?
| | Patient Selection | 1 | 2018 | 660 | 0.450 |
Why?
| | Endovascular Procedures | 1 | 2018 | 301 | 0.430 |
Why?
| | Algorithms | 2 | 2023 | 1617 | 0.420 |
Why?
| | Swine, Miniature | 1 | 2013 | 81 | 0.410 |
Why?
| | Insulin, Long-Acting | 2 | 2024 | 62 | 0.400 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 337 | 0.390 |
Why?
| | Humans | 37 | 2025 | 129847 | 0.350 |
Why?
| | Hospitalization | 3 | 2025 | 2079 | 0.350 |
Why?
| | Glucose | 3 | 2024 | 1003 | 0.330 |
Why?
| | Obesity | 6 | 2023 | 2885 | 0.330 |
Why?
| | Enteral Nutrition | 3 | 2024 | 186 | 0.320 |
Why?
| | Insulin, Isophane | 2 | 2024 | 21 | 0.320 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 340 | 0.320 |
Why?
| | Diabetes Complications | 2 | 2013 | 224 | 0.270 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 444 | 0.250 |
Why?
| | Dietary Fats | 3 | 2012 | 303 | 0.220 |
Why?
| | Middle Aged | 13 | 2025 | 31177 | 0.210 |
Why?
| | Male | 18 | 2025 | 63759 | 0.200 |
Why?
| | Heart Failure | 1 | 2016 | 2148 | 0.200 |
Why?
| | Factor Xa Inhibitors | 1 | 2024 | 170 | 0.200 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2006 | 259 | 0.200 |
Why?
| | Aged | 8 | 2025 | 22107 | 0.200 |
Why?
| | Female | 19 | 2025 | 68829 | 0.200 |
Why?
| | Treatment Outcome | 5 | 2019 | 10241 | 0.200 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.200 |
Why?
| | Rivaroxaban | 1 | 2024 | 252 | 0.190 |
Why?
| | Endocrinology | 1 | 2023 | 74 | 0.190 |
Why?
| | Diet | 3 | 2015 | 1212 | 0.190 |
Why?
| | Steroids | 1 | 2022 | 158 | 0.180 |
Why?
| | Postoperative Complications | 2 | 2024 | 2481 | 0.180 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 92 | 0.180 |
Why?
| | Risk Factors | 5 | 2019 | 9801 | 0.180 |
Why?
| | Dyslipidemias | 1 | 2023 | 177 | 0.180 |
Why?
| | Rural Population | 1 | 2025 | 521 | 0.180 |
Why?
| | Patient Admission | 1 | 2012 | 183 | 0.180 |
Why?
| | Anticholesteremic Agents | 2 | 2017 | 150 | 0.170 |
Why?
| | Dexamethasone | 1 | 2022 | 352 | 0.170 |
Why?
| | Pilot Projects | 1 | 2025 | 1597 | 0.160 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 53 | 0.160 |
Why?
| | Diet, Reducing | 2 | 1998 | 87 | 0.160 |
Why?
| | Diabetic Angiopathies | 1 | 2011 | 261 | 0.150 |
Why?
| | Dietary Carbohydrates | 4 | 2012 | 152 | 0.150 |
Why?
| | Inpatients | 1 | 2012 | 477 | 0.150 |
Why?
| | Double-Blind Method | 2 | 2024 | 1877 | 0.140 |
Why?
| | Critical Illness | 1 | 2024 | 759 | 0.140 |
Why?
| | United States | 5 | 2023 | 13913 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 279 | 0.140 |
Why?
| | Colorado | 2 | 2025 | 4410 | 0.130 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 102 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2016 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 610 | 0.130 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 59 | 0.130 |
Why?
| | Early Growth Response Protein 1 | 1 | 2006 | 28 | 0.130 |
Why?
| | Diet, Diabetic | 1 | 1996 | 35 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2023 | 979 | 0.130 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 81 | 0.120 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.120 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 42 | 0.110 |
Why?
| | Mexican Americans | 1 | 2015 | 113 | 0.110 |
Why?
| | Caloric Restriction | 2 | 2012 | 111 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 875 | 0.110 |
Why?
| | Hypertension | 1 | 2023 | 1242 | 0.110 |
Why?
| | Biomarkers | 3 | 2023 | 3971 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 314 | 0.110 |
Why?
| | Adiponectin | 1 | 2015 | 236 | 0.110 |
Why?
| | Quality of Life | 2 | 2023 | 2695 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2004 | 51 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 304 | 0.110 |
Why?
| | Signal Transduction | 4 | 2012 | 4935 | 0.100 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1067 | 0.100 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 1644 | 0.100 |
Why?
| | Androgens | 1 | 2004 | 177 | 0.100 |
Why?
| | Sirtuin 1 | 1 | 2012 | 30 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 203 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 592 | 0.100 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 104 | 0.090 |
Why?
| | Postmenopause | 1 | 2004 | 349 | 0.090 |
Why?
| | Weight Loss | 2 | 1998 | 740 | 0.090 |
Why?
| | Phosphorylation | 2 | 2013 | 1716 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 603 | 0.090 |
Why?
| | Estrogens | 1 | 2004 | 348 | 0.090 |
Why?
| | Arteries | 1 | 2013 | 266 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 149 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2024 | 14553 | 0.090 |
Why?
| | Adiposity | 1 | 2015 | 504 | 0.090 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 190 | 0.090 |
Why?
| | Swine | 1 | 2013 | 761 | 0.090 |
Why?
| | Vasodilation | 1 | 2013 | 476 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3269 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2006 | 1264 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 423 | 0.080 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 363 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2545 | 0.070 |
Why?
| | Cognition | 1 | 2004 | 1125 | 0.060 |
Why?
| | Phosphates | 1 | 2007 | 181 | 0.060 |
Why?
| | Cholesterol, LDL | 2 | 2017 | 358 | 0.060 |
Why?
| | Endocrinologists | 1 | 2023 | 12 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4077 | 0.050 |
Why?
| | Nonlinear Dynamics | 1 | 2023 | 88 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 355 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 146 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2004 | 1291 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 273 | 0.050 |
Why?
| | Insulin Glargine | 1 | 2012 | 81 | 0.050 |
Why?
| | Frailty | 1 | 2024 | 152 | 0.050 |
Why?
| | Albuminuria | 1 | 2012 | 183 | 0.050 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 295 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1042 | 0.050 |
Why?
| | Adult | 7 | 2016 | 35634 | 0.050 |
Why?
| | Animals | 5 | 2013 | 35409 | 0.040 |
Why?
| | Phenotype | 2 | 2023 | 3062 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2012 | 362 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2007 | 4102 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1212 | 0.040 |
Why?
| | Prospective Studies | 2 | 2021 | 7158 | 0.040 |
Why?
| | Adolescent | 2 | 2015 | 20451 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2024 | 7066 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 329 | 0.040 |
Why?
| | C-Peptide | 2 | 1998 | 163 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 485 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2023 | 738 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 531 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2012 | 413 | 0.040 |
Why?
| | Dietary Fats, Unsaturated | 1 | 1998 | 23 | 0.040 |
Why?
| | Cholesterol | 2 | 1998 | 412 | 0.040 |
Why?
| | Triglycerides | 2 | 1998 | 528 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 827 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 55 | 0.030 |
Why?
| | Young Adult | 3 | 2015 | 12467 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1872 | 0.030 |
Why?
| | Lipoproteins | 1 | 1998 | 172 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 21 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3089 | 0.030 |
Why?
| | Diet Surveys | 1 | 2015 | 92 | 0.030 |
Why?
| | Glucagon | 1 | 1996 | 105 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 151 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6550 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 1996 | 205 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 201 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 277 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2646 | 0.030 |
Why?
| | Lipids | 1 | 1998 | 628 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2004 | 119 | 0.030 |
Why?
| | Rats | 2 | 2007 | 5487 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 89 | 0.030 |
Why?
| | Androstadienes | 1 | 2003 | 106 | 0.030 |
Why?
| | Helminthiasis | 1 | 1993 | 11 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 1996 | 1201 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 756 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4896 | 0.020 |
Why?
| | Reference Values | 1 | 2004 | 796 | 0.020 |
Why?
| | Interleukin-4 | 1 | 1993 | 212 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 194 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 312 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1092 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 129 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 800 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1993 | 330 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2004 | 312 | 0.020 |
Why?
| | PPAR gamma | 1 | 2012 | 183 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1368 | 0.020 |
Why?
| | Cattle | 1 | 2003 | 978 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1204 | 0.020 |
Why?
| | Interferon-gamma | 1 | 1993 | 773 | 0.020 |
Why?
| | Cell Movement | 1 | 2003 | 950 | 0.020 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 24 | 0.020 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1465 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2012 | 3630 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5085 | 0.010 |
Why?
| | Risk | 1 | 2007 | 860 | 0.010 |
Why?
| | Kinetics | 1 | 2007 | 1645 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1998 | 38 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 998 | 0.010 |
Why?
| | Energy Intake | 1 | 1998 | 462 | 0.010 |
Why?
| | Antigens, Helminth | 1 | 1993 | 12 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 980 | 0.010 |
Why?
| | Chronic Disease | 1 | 1993 | 1724 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1993 | 1058 | 0.000 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|